Lanib 250mg

Lanib 250mg tablets are classified as an anti-cancer agent, which is an orally active drug used for treating breast cancer.

Chemically classified as quinazoline with strong anti-cancer effect and the tablet Lanib is a synthetic oral tablet

Normally targeted therapy or tyrosine kinase inhibitor drugs are capable of increasing the plasma aminotransferase levels which may lead to liver injury.

Lanib 250mg tablets are classified as;

1.Tyrosine kinase prohibition

2. Stop the HER2/neu& epidermal growth factor receptor activity

3.Targeted therapy

4.Signal transduction prohibition.

INDICATION

Primarily Lanib 250mg indicated for advanced breast cancer. Lanib is indicated for the combination with Capecitabine tablets are normally indicated for the treatment of metastatic breast cancer patients in whose cancer cells expressed with EGFR 2 (HER2) and already patients may get an anthracycline, taxane& Trastuzumab.

lanip 250mg,lanip 250mg tablet

DOSAGE

In HER2 positive advanced breast cancer:

The usual dose of Lanib 250mg tablet is 1250mg should be given orally as a single dose on day 1 to 21 repeatedly concomitant with Capecitabine 2000mg/m2/day (administer 2 doses relatively 12 hours apart orally ) on day 1 to 14 in a continuous 21-day cycle.

Sum of 5 tablets of Lanib should be given at a time as a whole.

Patients with hormone receptor-positive HER 2 positive advanced breast cancer:

The usual dose is 1500mg should be given orally as a single dose by combination with letrozole.

The usual dose of letrozole is 2.5mg as a once daily

Administer 6 tablets of Lanib 250mg in this condition

Dose alteration:

Cardiac events:

Left ventricular ejection fraction with grade 2 reduction in patients is given treatment with Lanib 250mg tablet should be discontinued. In this condition, the dose of Lanib should be started with 1000mg/day in combining with Capecitabine; whereas in combination with letrozole the dose of Lanib restated with 1250mg/day after 2 weeks, if LVEF turns to normal.

Hepatic impairment:

Severe hepatic impairment in patients, the dose reduced from 1250mg/day to 750mg/day or from 1500mg/day to 1000mg/day. Administer the Lanib tablet without food as 1 hour before or 2 hours after the uptake of food.

PHARMACOLOGY

Chemically Lanib 250mg tablet is classified as 4-anilinoquinazoline derivative, that evacuates anti-cancer activity by inhibiting intracellular tyrosine kinase domains of EFGR & HER type 2.

The ErbB forced cancer cell production has been prevented by Lapatinib.

This growth factor receptor present on the cell surface of cancer mass which may lead to cause cell death.

Absorption :

Incomplete and insufficient absorption, the time to peak plasma concentration is 4 hours after intake of the drug.

Distribution :

The drug bounds to human plasma protein like albumin & alpha glycoprotein relatively 99%.

Metabolism :

Lanib 250mg is a substrate of P-gp& BCRP and goes through intensive metabolism by using CYPP3A4 & CYP3A5 with a minimum contribution of CYP2C19 & CYP2C8.

Excretion :

Elimination occurs via feces & urine

Half-life time in 14.2 hours reaches by a single dose of Lanib and multiple dosing reaches in 24 hours.

PRECAUTION

Reduction in left ventricular ejection fraction:

While using Lanib 250mg in a patient with LVEF Caution should be taken

The resentment of LVEF should be decreased within the first 12 weeks of treatment

Before starting the therapy with Lanib, the patient must be monitor thoroughly if suspected with LVEF or not.

Liver damage:

Raising the level of AST, ALT or bilirubin may cause liver injury

To inhibits this condition, periodic LFT should be control

Diarrhea:

Serious diarrhea may cause to dehydration leads death also; if a patient does not recover from this severity must stop with this therapy.

Interstitial lung disease:

The patient should be check with pulmonary symptoms and give supportive measures.

On Serious condition, treatment should be discontinuing

QT prolongation:

Balance ECG periodically

Give the patient substituent for this adverse condition

Hypokalemia and hypomagnesemia correction should take place

Cutaneous reactions:

Some life-threatening reactions may occur, in this condition, therapy should be discontinued

Embryo-fetal damage:

Lanib 250mg leads to fetal damage and produces some deformities.

During therapy Patient should advice not getting pregnant.

DRUG INTERACTION

The drug Lanib is the prohibition of CYP3A4, CYP2C8 & P-gp drug transporters; a weak inhibitor of CYP3A4.

Interaction of Midazolam withLanib increases the exposure of Midazolam

Interaction of Paclitaxel will Increase in paclitaxel exposure occurs while concomitant with Lanib

Digoxin interaction with Lanib 250mg then the Serum digoxin concentration should be examined periodically prior to starting the concomitant use

A drug that induces or inhibit CYP3A4 enzymes:

If the interaction of Lanib 250mg tablets with CYP3A4 inducers or inhibitors, alteration of the dose is necessary.

Interaction of Ketaconazole with Lanib 250mg, the dose reduced to 200mg as two times a day for 7 days.

Interaction of Carbamazepine with Lanib, the dose of carbamazepine at 100mg as a two times a day for 3 days & 200mg for two times a day for 17 days, the exposure of Lanib reduced to 72%.

Concomitant use of Lanib with P-gp inhibitors causes increasing the concentration of Lapatinib

CONTRAINDICATION

The patients who are contraindicated to the component present in Lanib 250mg tablet then Hypersensitivity reaction occurs

MISSED DOSE

If missed a dose the have it as soon possible or Missed dose should be swapped and continue the regular dosing schedule for avoiding adverse conditions. If missed dose occurs, it should not be resumed and continue the next schedule.

OVERDOSAGE

The doses of Lanib 250mg tablet range from 2500mg to 9000mg daily, the duration of therapy should be varied between 1 & 17 days. Symptoms occurred during an overdose of Lanib are; Sore scalp, sinus tachycardia & mucosal inflammation. Patients should be providing supportive measures.

STORAGE

Store the drug at 25℃ (77℃). Protect free from moisture, heat or light

SIDE EFFECTS

Stomatitis, Dyspepsia, Diarrhea, Nausea, Vomiting, Liver toxicity, Interstitial lung disease, Anaphylactic reactions, Stevens-Johnson syndrome, Ventricular arrhythmias, QT prolongation, Palmar-plantar erythrodysesthesia, Rash, Dry skin, Mucosal inflammation, Musculoskeletal pain in extremity, Back pain, Dyspnea, Insomnia, Alopecia, Pruritus, Nail disorders, Asthenia, Headache, Epistaxis, Elevation of hemoglobulin, platelets, neutrophils, Increase in AST & ALT, bilirubin, Reduction of left ventricular ejection fraction.

Contact Details

Phone : +91-9987711567

Email :applepharmaceutical@gmail.com

Email :info@myapplepharma.com